Labiotech.eu

What treatments are in store to treat Charcot-Marie-Tooth disease? 💊 Charcot-Marie-Tooth disease is a group of inherited disorders that cause nerve damage. While treatments exist to help manage some symptoms, there is no cure and patients have various unmet needs. 😨 Despite Pharnext’s phase 3 fail, there are a number of candidates being trialed at the moment. 🔍 🏥 These include NMD Pharma A/S’s NMD670 and Sarepta Therapeutics’ NT-3. And poised to enter the clinic are Novartis’ DTx-1252 and Actio Biosciences, Inc.’ drug candidate. Read our latest article to find out more about the therapeutic space! 👇 https://lnkd.in/ejC6dkY2 #CharcotMarieTooth #CMTDisease #rarediseaseawareness #neurologicaldisorders #nervehealth #therapeuticadvances #biotechbreakthroughs Helixmith | Vanda Pharmaceuticals | Chong Kun Dang Pharm. | University of Miami

Could cryopreservation solve Europe’s cell therapy logistics challenges? ❄️ With Cryoport Systems’ IntegriCell services now in Belgium, Europe’s cell and gene therapy sector gains a critical infrastructure boost. This expansion helps standardize cryopreservation, making it easier for therapy developers to transport and maintain the quality of leukapheresis-derived cell materials across borders. 🧫 By localizing storage and enhancing logistical efficiency, IntegriCell strengthens Europe’s ATMP (advanced therapy medicinal product) pipeline from clinical trials to commercialization. ✅ Read more here ⬇️ https://lnkd.in/d3GnCPuR #cryopreservation #celltherapy #ATMP #CAR-T #biotechinnovation #IntegriCell #medicalinnovation

Are these miRNA companies on your radar? 🧭 MicroRNAs (miRNAs) are tiny molecules making big waves in biotech, thanks to their ability to regulate gene expression and address complex diseases. From targeting neurodegenerative disorders to tackling metabolic conditions, miRNA-based therapeutics are offering new solutions in various areas. 🧠🫀 Their promise lies in precision—modulating specific gene pathways while minimizing off-target effects. Recent advancements in delivery systems, like nanoparticles and tailored oligonucleotides, are breaking down barriers, allowing therapies to reach their intended targets more effectively. 🎯 Take a look at seven companies in this space! ⬇️ https://lnkd.in/dtHcwZzF #miRNA #biotech #genetherapy #precisionmedicine #metabolichealth #biotechnology #nanoparticles #oligonucleotides #medicalinnovation #futureofmedicine aceRNA Technologies | ARTHEx Biotech | BIORCHESTRA Co., Ltd. | Cardior Pharmaceuticals | Ceria Therapeutics | Resalis Therapeutics | TransCode Therapeutics, Inc.

Are ADCs the future of cancer treatment? 🚀 Antibody-drug conjugates (ADCs) are reshaping the oncology landscape, combining the precision of monoclonal antibodies with the potency of chemotherapeutics. Despite their promise, their journey to clinical success is challenging. From optimizing linker technologies to ensuring targeted delivery with minimal off-target effects, every step requires meticulous planning. 💡 Allucent’s latest insights reveal key strategies for ADC development, including navigating regulatory pathways and leveraging cutting-edge technologies to improve efficacy and safety. With advancements like bispecific ADCs gaining traction, the potential to overcome tumor heterogeneity is closer than ever. 🔬 Read more below! ⬇️ https://lnkd.in/dmUUXcdB   #ADCtherapies #oncologyinnovation #cancerresearch #targetedtherapies #precisionmedicine #bispecificADCs #pharmabreakthroughs #drugdevelopment

🚀 Ready to connect with biotech leaders in 2025? Check out our list of key biotech conferences & events happening worldwide—ideal for networking and partnering with decision-makers in biopharma. 🧬 https://lnkd.in/dm2xjYiB #biotechevents2025 #biotechconferences #biopharmaleaders #globalbiotech #pharmainnovation #biotechleadership #networking

Is Evotec getting acquired? 🤝 2024 hasn’t been kind to Evotec, which had to lay off staff and close its gene therapy operations. This hasn’t gone unnoticed, and a couple of players are making their move on the German company. Triton Partner, an Evotec investor, raised its shares to 10% and became the company’s largest investor. Not long after, Halozyme Therapeutics made an unsolicited acquisition offer. 💸 While nothing is decided yet, it seems that an acquisition in the future is likely. But what would that mean for the biotech industry? Would Evotec’s unique model – part service provider, part innovator – be carried out if it were to be acquired? 🤔 Read more below! ⬇️ https://lnkd.in/dd7dq5KG   #biotechacquisition #pharmainvestments #biotechnews #lifesciences #biotechinnovation #futureofbiotech #biotechpartnerships

Weekly Recap of the Hottest M&A and Partnerships in the Biotech World! 🔥🤝 Merger and acquisition: 🔀                                                                                🇩🇪 BioNTech SE to acquire 🇨🇳 Biotheus Inc. | BioNTech to pay $800 million and up to $150 million in milestones | Lead asset acquired: PD-L1-targeting antibody in phase 2 Partnering: 🤝 🇺🇸 Merck signs licensing deal with 🇨🇳 LaNova Medicines for anti-PD-1/VEGF bispecific antibody |  LaNova to receive $588 million upfront and up to $2.7 billion in milestones 🇺🇸 Avenzo Therapeutics and 🇨🇳 VelaVigo partner to develop, manufacture, and commercialize bispecific antibody-drug conjugate | VelaVigo to receive up to $800 million in upfront and milestone payments 🇺🇸 Ratio Therapeutics collaborates with 🇨🇭 Novartis for SSTR2-targeting radiotherapeutic candidate | Ratio to receive up to $745 million in upfront and milestone payments 🇨🇭 Numab Therapeutics AG and 🇯🇵 Kaken Pharmaceutical Co Ltd collaborate for antibody to treat inflammatory bowel disease | Numab to receive CHF 13 million ($14.68 million) upfront 🇬🇧 Healx partners with 🇫🇷 Sanofi to identify new disease indications using AI drug discovery platform | undisclosed financial terms Subscribe to our newsletter for more partnering updates!  🔗 https://lnkd.in/dsgz62YY #deals #partnering #mergers #acquisitions #biotech

Have you heard about the recent acclaim for Google DeepMind’s new platform, AlphaFold3? 🧬🤖 Going one step further than its predecessor AlphaFold2, the new model is able to predict protein-protein interactions with high precision, offering researchers a deeper understanding of how proteins form complexes and carry out their biological functions. 🔬 As DeepMind recently made AlphaFold3 open-source, academics can now realize its full potential to revolutionize the field of drug discovery. 💊 Read our latest article to find out everything you need to know about AlphaFold3! 👇️ https://lnkd.in/dgZW9TEc #proteininteractions #drugdiscovery #proteincomplexes #bioinformatics #biotechinnovation #medicalbreakthroughs #futureofmedicine Yvonne Tan, Ph.D | Nuclera | Isomorphic Labs

Could antigen modulation address autoimmune diseases? 🤔 Immunology is a key area in biotech and biopharma, both in terms of R&D and sales. 💰 However, according to UK-headquartered Greywolf Therapeutics, the industry has only focused on two-thirds of the puzzle. 🧩 Grey Wolf Therapeutics is the first company to explore changing signal 1 to induce an immunological effect – antigen recognition. 👀 💬 Labiotech has been in conversation with Grey Wolf’s CEO Peter Joyce to find out about what the biotech is pioneering. 🚀 🎧 Tune in to the latest episode of the Beyond biotech Podcast to learn more! 👇 https://lnkd.in/d5jsXquD #BeyondBiotechPodcast #autoimmunediseases #immunology #antigenmodulation #biotechinnovation #medicalbreakthroughs #autoimmuneresearch

💰 Biotech's Top Investments This Week! 🚀 🇺🇸 Metsera | $215 million series B | GLP1 medicines | phase 2 in obesity 🇨🇳 🇺🇸 Zai Lab | $200 million public offering | drug development | phase 3 in non-small cell lung cancer 🇺🇸 TRexBio | $84 million series B | tissue regulation | phase 1 in autoimmune and inflammatory diseases 🇧🇪 atbtherapeutics | €54 million ($56.96 million) series A | antibodies 🇩🇰 Freya Biosciences | $10.4 million series A | women’s healthcare | phase 1 in vaginal dysbiosis 🇺🇸 Calidi Biotherapeutics | $7.5 million public offering | immunotherapies | phase 1 in glioma Subscribe to our newsletter for more fundraising updates! 🔗 https://lnkd.in/dsgz62YY #fundraising #funding #biotech #venturecapital #fundinground #biotechstartup #seriesa #seriesb #seriesc #investors #IPO #seedfunding